Article
HLA-A∗03:01 as predictive genetic biomarker for glatiramer acetate treatment response in multiple sclerosis: a retrospective cohort analysis.
EBioMedicine - 1 Aug 2025
Zhang Brian C, Schneider-Hohendorf Tilman, Elyanow Rebecca, Pignolet Beatrice, Falk Simon, Wünsch Christian, Deffner Marie, Yusko Erik, May Damon, Mattox Daniel, Dawin Eva, Gerdes Lisa Ann, Bucciarelli Florence, Revie Lisa, Antony Gisela, Jarius Sven, Seidel Christiane, Senel Makbule, Bittner Stefan, Luessi Felix, Havla Joachim, Knop Matthias, Friese Manuel A, Rothacher Susanne, Salmen Anke, Hayashi Fumie, Henry Roland, Caillier Stacy, Santaniello Adam, Seipelt Maria, Heesen Christoph, Nischwitz Sandra, Bayas Antonios, Tumani Hayrettin, Then Bergh Florian, Meyer Zu Hörste Gerd, Kümpfel Tania, Gross Catharina C, Wildemann Brigitte, Kerschensteiner Martin, Gold Ralf, Meuth Sven G, Zipp Frauke, Cree Bruce A C, Oksenberg Jorge, Wilson Michael R, Hauser Stephen L, Zamvil Scott S, Klotz Luisa, Liblau Roland, Robins Harlan, Sabatino Joseph J, Wiendl Heinz, Schwab Nicholas
Abstract excerpt
BACKGROUND: Glatiramer acetate (GA) is a well-tolerated treatment for multiple sclerosis (MS) and comparable in its efficacy to high-dose interferon beta (IFN). As a lack of validated treatment response biomarkers for MS hampers progress in personalised treatment, the study goal was to search for biomarkers of a successful treatment response utilising the known observation of T-cell expansions after GA treatment....
Read the complete abstract on PubMed